Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT06392425
Role of Serum ADAM 17 (A Disintegrin And Metalloprotease 17) and Caspase 3 in Patients With Chronic Kidney Disease
Sponsor: Assiut University
View on ClinicalTrials.gov
Summary
1. To evaluate clinical utility of Serum ADAM 17 (A disintegrin and metalloprotease 17) and Caspase 3 measurement in chronic kidney disease patients 2. Study relationship of serum ADAM 17 and Caspase 3 to stages of chronic kidney disease 3. Compare serum ADAM 17 and Caspase 3 levels in Diabetic Chronic kidney disease patients and Non Diabetic Chronic kidney disease patients
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
OBSERVATIONAL
Enrollment
90
Start Date
2024-04-26
Completion Date
2027-10-31
Last Updated
2024-05-01
Healthy Volunteers
Not specified
Conditions
Interventions
OTHER
caspase 3 and ADAM 17 biomarkers
Role of caspase 3 and ADAM 17 biomarkers in chronic kidney disease